Literature DB >> 10791260

Ocular neovascularization in patients with uveitis.

I C Kuo1, E T Cunningham.   

Abstract

Neovascularization is an infrequent but serious complication of uveitis. The retina and optic disk appear to be affected most often, although new blood vessels may arise from the iris, ciliary body, and choroid as well. Although neovascularization can usually be identified on careful clinical examination, some patients may require fluorescein angiography or UBM. Numerous neovascular growth and inhibitory factors have been identified experimentally. Clinically, however, uveitic neovascularization appears to be determined most directly by the severity of the inflammation and the presence of retinal nonperfusion. Virtually all patients with uveitic neovascularization deserve a trial of local or systemic corticosteroids. Laser photocoagulation can be considered in those patients who fail to respond to corticosteroid therapy, but only when retinal nonperfusion has been demonstrated on fluorescein angiography. Surgical excision of newly formed vessels is reserved for selected patients with CNV and uveitis, but should only be considered when corticosteroids and focal photocoagulation are ineffective or are otherwise contraindicated.

Entities:  

Mesh:

Year:  2000        PMID: 10791260     DOI: 10.1097/00004397-200004000-00009

Source DB:  PubMed          Journal:  Int Ophthalmol Clin        ISSN: 0020-8167


  16 in total

1.  Serpiginous choroidopathy presenting as choroidal neovascularisation.

Authors:  D K Lee; E B Suhler; W Augustin; R R Buggage
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  Risk of Retinal Neovascularization in Cases of Uveitis.

Authors:  Apurva K Patel; Craig W Newcomb; Teresa L Liesegang; Siddharth S Pujari; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; H Nida Sen; Pichaporn Artornsombudh; Srishti Kothari; John H Kempen
Journal:  Ophthalmology       Date:  2015-12-11       Impact factor: 12.079

3.  Inflammatory choroidal neovascularization.

Authors:  Piergiorgi Neri; Marta Lettieri; Cinzia Fortuna; Mara Manoni; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

Review 4.  Angiogenesis in eye disease: immunity gained or immunity lost?

Authors:  Thomas A Ferguson; Rajendra S Apte
Journal:  Semin Immunopathol       Date:  2008-02-23       Impact factor: 9.623

5.  An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.

Authors:  Lei Feng; Jiang-Hua Hu; Jie Chen; Xin Xie
Journal:  J Zhejiang Univ Sci B       Date:  2018 Apr.       Impact factor: 3.066

Review 6.  Verteporfin PDT for non-standard indications--a review of current literature.

Authors:  Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

7.  Macrophages inhibit neovascularization in a murine model of age-related macular degeneration.

Authors:  Rajendra S Apte; Jennifer Richter; John Herndon; Thomas A Ferguson
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

Review 8.  Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy.

Authors:  Enzo D'Ambrosio; Paolo Tortorella; Ludovico Iannetti
Journal:  J Ophthalmol       Date:  2014-04-27       Impact factor: 1.909

9.  Choroidal neovascularization secondary to tubulointerstitial nephritis and uveitis syndrome (TINU) in an adult patient.

Authors:  Hans Barron Heymann; Daniel Colon; Manjot K Gill
Journal:  J Ophthalmic Inflamm Infect       Date:  2015-10-07

10.  A case of choroidal neovascular membrane in 6-year-old boy with juvenile idiopathic arthritis.

Authors:  Parthopratim Dutta Majumder; Avirupa Ghose; Chetan Rao; Muna Bhende; Jyotirmay Biswas
Journal:  J Ophthalmic Inflamm Infect       Date:  2017-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.